Compare KMDA & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMDA | DNA |
|---|---|---|
| Founded | 1990 | 2008 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 460.3M | 458.6M |
| IPO Year | 2013 | 2020 |
| Metric | KMDA | DNA |
|---|---|---|
| Price | $8.41 | $7.00 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $14.00 | $8.50 |
| AVG Volume (30 Days) | 158.3K | ★ 1.3M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | N/A | ★ 46.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $170,155,000.00 |
| Revenue This Year | $13.94 | N/A |
| Revenue Next Year | $9.84 | N/A |
| P/E Ratio | $24.59 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.50 | $5.37 |
| 52 Week High | $9.35 | $17.58 |
| Indicator | KMDA | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 66.08 | 44.65 |
| Support Level | $8.38 | $6.30 |
| Resistance Level | $8.57 | $7.10 |
| Average True Range (ATR) | 0.25 | 0.48 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 81.01 | 40.67 |
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.